Tambjamines as Fast-Acting Multistage Antimalarials

Well-tolerated and novel antimalarials that can combat multiple stages of the parasite life cycle are desirable but challenging to discover and develop. Herein, we report results for natural product-inspired novel tambjamine antimalarials. We show that they are potent against liver, asexual erythrocytic, and sexual erythrocytic parasite life cycle stages. Notably, our lead candidate <b>1</b> (KAR425) displays excellent oral efficacy with complete clearance of parasites within 72 h of treatment in the humanized <i>Plasmodium falciparum</i> (NOD-scid) mouse model at 50 mg/kg × 4 days. Profiling of compound <b>1</b> demonstrated a fast <i>in vitro</i> killing profile. In addition, several other tambjamine analogues cured erythrocytic <i>Plasmodium yoelii</i> infections after oral doses of 30 and 50 mg/kg × 4 days in a murine model while exhibiting good safety and metabolic profiles. This study presents the first account of multiple-stage antiplasmodial activities with rapid killing profile in the tambjamine family.

Authors

Institutions

Publication Details

Journal
ACS Infectious Diseases
Published
2024-11-11
DOI
https://doi.org/10.1021/acsinfecdis.4c00659
Citations
5
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tambjamines as Fast-Acting Multistage Antimalarials

Roland A. Cooper, Amrendra Kumar, Pamela Orjuela-Sánchez, Diana Caridha et al.
5 citations
ACS Infectious Diseases
Malaria Research and Control
2.71
article

Tambjamines as Fast-Acting Multistage Antimalarials

Roland A. Cooper, Amrendra Kumar, Pamela Orjuela-Sánchez, Diana Caridha, Chad Black, Brandon Pybus, Jane X. Kelly, Xiannu Jin, R. Lee Kirby, Jake Baum, Susan E. Leed, Jesse DeLuca, Yuexin Li, Jason Sousa, Frida G. Ceja, Matthias Rottmann, Cameron Blount, Martin Evans, Michael S. Madejczyk, Patricia Lee, Holly Matthews, Stephanie A. Rasmussen, Kevin A. Reynolds, Papireddy Kancharla, Robert J. Nadeau, Christina K. Nolan, Stephan Meister, Rozalia A. Dodean, Alison Roth, Hieu Dinh, Michael J. Delves, James Duffy, Philip J. Rosenthal, Patrick K. Tumwebaze, Elizabeth A. Winzeler, Chau Vuong, Jeremy N. Burrows, David H. Peyton, Ravi Chetree, Monica Martin, William E. Dennis, Kristina Pannone
article en
5 citations

Abstract

Well-tolerated and novel antimalarials that can combat multiple stages of the parasite life cycle are desirable but challenging to discover and develop. Herein, we report results for natural product-inspired novel tambjamine antimalarials. We show that they are potent against liver, asexual erythrocytic, and sexual erythrocytic parasite life cycle stages. Notably, our lead candidate <b>1</b> (KAR425) displays excellent oral efficacy with complete clearance of parasites within 72 h of treatment in the humanized <i>Plasmodium falciparum</i> (NOD-scid) mouse model at 50 mg/kg × 4 days. Profiling of compound <b>1</b> demonstrated a fast <i>in vitro</i> killing profile. In addition, several other tambjamine analogues cured erythrocytic <i>Plasmodium yoelii</i> infections after oral doses of 30 and 50 mg/kg × 4 days in a murine model while exhibiting good safety and metabolic profiles. This study presents the first account of multiple-stage antiplasmodial activities with rapid killing profile in the tambjamine family.

ACS Infectious DiseasesVol. 10(12)
University of London (GB), Portland State University (US), Swiss Tropical and Public Health Institute (CH), Dominican University of California (US), University of California, San Francisco (US), University of Basel (CH), Portland VA Medical Center (US), UNSW Sydney (AU), University of California San Diego (US), London School of Hygiene & Tropical Medicine (GB), Infectious Diseases Research Collaboration (UG), Imperial College London (GB), Medicines for Malaria Venture (CH), Walter Reed Army Institute of Research (US)
Wellcome Trust, Medicines for Malaria Venture, National Institutes of Health, Medical Research Council, National Institute of Allergy and Infectious Diseases
Openalex Percentile: Top 9%
Malaria Research and Control
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.